OneSource, Formycon Partner on Biosimilar Manufacturing

OneSource Specialty Pharma Limited, a multi-modality specialty pharma CDMO, and Formycon AG, an independent biosimilar developer headquartered in Munich, have entered a strategic manufacturing partnership for biosimilars.

Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its biologics’ facility in Bangalore. The collaboration brings together Formycon’s Biosimilar development experience with OneSource’s end-to-end biologics manufacturing expertise to support Formycon’s biosimilar programs for global markets.

Neeraj Sharma, Managing Director and CEO, OneSource Specialty Pharma, said: “This partnership brings together Formycon’s development expertise and OneSource’s integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacture of world-class biologics.”

Dr. Stefan Glombitza, CEO of Formycon AG, said: “By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies.”